Investment analysts at Lifesci Capital issued their Q1 2025 earnings per share (EPS) estimates for shares of Perspective ...

In a report released today, Charles Zhu from LifeSci Capital maintained a Hold rating on Repare Therapeutics (RPTX – Research Report). The ...

Fintel reports that on March 12, 2025, LifeSci Capital initiated coverage of Monte Rosa Therapeutics (NasdaqGS:GLUE) with a Outperform recommendation. Analyst Price Forecast Suggests 145.23% Upside As ...

Equities research analysts at Lifesci Capital issued their FY2024 earnings per share (EPS) estimates for shares of Immunome in a note issued to investors on Tuesday, March 11th. Lifesci Capital ...

In a report released today, Charles Zhu from LifeSci Capital initiated coverage with a Buy rating on Protara Therapeutics (TARA – Research ...

Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Immunome (NasdaqCM:IMNM) with a Outperform recommendation. Analyst Price Forecast Suggests 250.92% Upside As of March 4 ...

Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Protara Therapeutics (NasdaqGM:TARA) with a Outperform recommendation. As of March 4, 2025, the average one-year price ...

LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of $30.00. The company’s shares clo ...

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- LifeSci Communications today announced key leadership appointments and promotions designed to support its continued growth and strengthen its service ...

In addition to LifeSci Capital, Zymeworks also received a Buy from J.P. Morgan’s Brian Cheng in a report issued on March 6. However, on March 7, H.C. Wainwright reiterated a Hold rating on ...

Virtus LifeSci Biotech Products ETF earns a Below ... expanding its alternative offerings through its 2021 Westchester Capital Management acquisition and its 2023 purchase of AlphaSimplex.

The firm decreased its portfolio allocation in IMNM by 15.15% over the last quarter. EcoR1 Capital holds 3,879K shares representing 4.74% ownership of the company. No change in the last quarter.